Tassilo Bonzel1, Volker Schächinger2, Hilmar Dörge3. 1. Medical Clinic I, Cardio-Thoracic Center, Klinikum Fulda, Pacelliallee 4, 36043, Fulda, Germany. tassilo@bonzel.de. 2. Medical Clinic I, Cardio-Thoracic Center, Klinikum Fulda, Pacelliallee 4, 36043, Fulda, Germany. 3. Clinic for Cardiothoracic Surgery, Cardio-Thoracic Center, Klinikum Fulda, Fulda, Germany.
Abstract
OBJECTIVE AND BACKGROUND: We present a first description of a Heart Team (HT)-guided approach to coronary revascularization and its long-term effect on clinical events after percutaneous coronary intervention (PCI). The HT approach is a structured process to decide for coronary bypass grafting (CABG), PCI or conservative therapy in ad hoc situations as well as in HT conferences. As a hypothesis, during the long-term course after a PCI performed according to HT rules, a low number of late revascularizations, especially CABGs, are expected (F-PCI study). METHODS: In this monocentric study, the HT approach to an all-comer population was first analyzed and described in general with the help of a database. Next the use of a HT approach was described for a more homogeneous subgroup with newly detected CAD (1.CAD). Those patients in whom the HT decision was PCI (which was a 1.PCI) were then studied with the help of questionnaires for clinical events during a very long-term follow-up. Events were CABG, PCI, diagnostic catheterization (DCath) and death. RESULTS: A significant number of patients were presented to HT conferences: 22 % out of all 11,174 catheterizations, 24 % out of all 7867 CAD cases and 35 % out of 3408 1.CAD cases. Most of these patients had multi-vessel disease (MVD). Conference decisions were isolated CABG in 46-66 %, PCI in 10-14 %, valvular surgery in 9-16 %, HTx in 10-21 % (Endstage heart failure candidates for surgery) and conservative therapy (Medical or no therapy, additional diagnostic procedures or no adherence to recommended therapy) in 2-3 %. However, most PCIs, ad hoc and elective, were performed under Heart Team rules, but without conference. During follow-up of 1.PCI patients (Kaplan-Meier analysis), CABG occurred in only 15 % of patients, PCI in 37 % and DCath in 65 %; mortality of any course was 51 %. Mortalities were similar in one-vessel disease and in a population of the same year, matched for age and sex (p < 0.057), but mortality was higher in 1.PCI patients with MVD (p < 0.001). Beyond 2 years, Kaplan-Meier curves were linear. CONCLUSION: The structured Heart Team approach is an effective tool for ad hoc and conference-based clinical decision-making with a sustained clinical benefit. This is demonstrated in low late CABG (and PCI) rates after a 1.PCI, without elevated mortality. The all-comer population supports the universal value of these data. Stable annual event rates late after PCI suggest a conversion to stable CAD. Heart Team conferences are also important tools in cases of valvular and end-stage heart disease.
OBJECTIVE AND BACKGROUND: We present a first description of a Heart Team (HT)-guided approach to coronary revascularization and its long-term effect on clinical events after percutaneous coronary intervention (PCI). The HT approach is a structured process to decide for coronary bypass grafting (CABG), PCI or conservative therapy in ad hoc situations as well as in HT conferences. As a hypothesis, during the long-term course after a PCI performed according to HT rules, a low number of late revascularizations, especially CABGs, are expected (F-PCI study). METHODS: In this monocentric study, the HT approach to an all-comer population was first analyzed and described in general with the help of a database. Next the use of a HT approach was described for a more homogeneous subgroup with newly detected CAD (1.CAD). Those patients in whom the HT decision was PCI (which was a 1.PCI) were then studied with the help of questionnaires for clinical events during a very long-term follow-up. Events were CABG, PCI, diagnostic catheterization (DCath) and death. RESULTS: A significant number of patients were presented to HT conferences: 22 % out of all 11,174 catheterizations, 24 % out of all 7867 CAD cases and 35 % out of 3408 1.CAD cases. Most of these patients had multi-vessel disease (MVD). Conference decisions were isolated CABG in 46-66 %, PCI in 10-14 %, valvular surgery in 9-16 %, HTx in 10-21 % (Endstage heart failure candidates for surgery) and conservative therapy (Medical or no therapy, additional diagnostic procedures or no adherence to recommended therapy) in 2-3 %. However, most PCIs, ad hoc and elective, were performed under Heart Team rules, but without conference. During follow-up of 1.PCI patients (Kaplan-Meier analysis), CABG occurred in only 15 % of patients, PCI in 37 % and DCath in 65 %; mortality of any course was 51 %. Mortalities were similar in one-vessel disease and in a population of the same year, matched for age and sex (p < 0.057), but mortality was higher in 1.PCI patients with MVD (p < 0.001). Beyond 2 years, Kaplan-Meier curves were linear. CONCLUSION: The structured Heart Team approach is an effective tool for ad hoc and conference-based clinical decision-making with a sustained clinical benefit. This is demonstrated in low late CABG (and PCI) rates after a 1.PCI, without elevated mortality. The all-comer population supports the universal value of these data. Stable annual event rates late after PCI suggest a conversion to stable CAD. Heart Team conferences are also important tools in cases of valvular and end-stage heart disease.
Authors: Whady Hueb; Neuza Lopes; Bernard J Gersh; Paulo R Soares; Expedito E Ribeiro; Alexandre C Pereira; Desiderio Favarato; Antonio Sérgio C Rocha; Alexandre C Hueb; Jose A F Ramires Journal: Circulation Date: 2010-08-23 Impact factor: 29.690
Authors: Alfredo E Rodriguez; Julio Baldi; Carlos Fernández Pereira; Jose Navia; Máximo Rodriguez Alemparte; Alejandro Delacasa; Federico Vigo; Daniel Vogel; William O'Neill; Igor F Palacios Journal: J Am Coll Cardiol Date: 2005-08-16 Impact factor: 24.094
Authors: Patrick W Serruys; Andrew T L Ong; Lex A van Herwerden; J Eduardo Sousa; Adib Jatene; Johannes J R M Bonnier; Jacques P M A Schönberger; Nigel Buller; Robert Bonser; Clemens Disco; Bianca Backx; Paul G Hugenholtz; Brian G Firth; Felix Unger Journal: J Am Coll Cardiol Date: 2005-08-16 Impact factor: 24.094
Authors: Patrick W Serruys; Yoshinobu Onuma; Scot Garg; Pascal Vranckx; Bernard De Bruyne; Marie-Claude Morice; Antonio Colombo; Carlos Macaya; Gert Richardt; Jean Fajadet; Christian Hamm; Monique Schuijer; Tessa Rademaker; Kristel Wittebols; Hans Peter Stoll Journal: J Am Coll Cardiol Date: 2010-02-18 Impact factor: 24.094
Authors: Friedrich W Mohr; Marie-Claude Morice; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; Marie-angèle Morel; Nic Van Dyck; Vicki M Houle; Keith D Dawkins; Patrick W Serruys Journal: Lancet Date: 2013-02-23 Impact factor: 79.321
Authors: Stuart N Hoffman; John A TenBrook; Michael P Wolf; Stephen G Pauker; Deeb N Salem; John B Wong Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: Szymon Jonik; Michał Marchel; Zenon Huczek; Janusz Kochman; Radosław Wilimski; Mariusz Kuśmierczyk; Marcin Grabowski; Grzegorz Opolski; Tomasz Mazurek Journal: J Pers Med Date: 2022-04-28
Authors: Szymon Jonik; Michał Marchel; Ewa Pędzich-Placha; Arkadiusz Pietrasik; Adam Rdzanek; Zenon Huczek; Janusz Kochman; Monika Budnik; Radosław Piątkowski; Piotr Scisło; Paweł Czub; Radosław Wilimski; Jakub Maksym; Marcin Grabowski; Grzegorz Opolski; Tomasz Mazurek Journal: Int J Environ Res Public Health Date: 2022-03-25 Impact factor: 3.390
Authors: Michael N Young; Dhaval Kolte; Mary E Cadigan; Elizabeth Laikhter; Kevin Sinclair; Eugene Pomerantsev; Michael A Fifer; Thoralf M Sundt; Robert W Yeh; Farouc A Jaffer Journal: J Am Heart Assoc Date: 2020-04-20 Impact factor: 5.501